Financial Results for the Fiscal Year Ended March 31, 2020 (FY2019)
COVID-19 Response and Mid- to Long-term Indications

from the beginning

Financial Results for the Fiscal Year Ended March 31, 2020 (FY2019)

• Despite the COVID-19 Impact, Highest-ever Revenue and Operating Profit

• FY19 Results in Comparison to the Original Guidance

• Adjusted Operating Profit Variance Analysis

• Revenue by Region

• Revenue by Business Segment

• Cardiac and Vascular: Double Digit Growth in Revenue and Profit Excluding FX

• General Hospital: Revenue and Profit in Line with the Guidance

• Blood and Cell Technologies: Exceeded the Guidance Excluding FX Impact

• FY19 Year-end Dividend Proposal: 14.0 JPY

• Major Topics in FY19 Q4

• All Companies Contribute to COVID-19 Prevention and Treatment

• FY19 New Product Pipeline

• FY20 Annual Guidance

• The COVID-19 Framework of Cardiac and Vascular Procedures

• Limited COVID-19 Impact on GH and TBCT

• FY20 New Product Pipeline

• FY20 Liquidity and Cash Allocation

Reference

• FY19 Revenue and Growth by Region

• Operating Expenses

• Quarterly Results

• Adjusted Operating Profit: Adjustments

• CAPEX and R&D Expenses

• Cash Flows

• Foreign Exchange Sensitivity

• The Status of Convertible Bonds

@

COVID-19 Response and Mid- to Long-term Indications

• Basic Policy for COVID-19 Response

• Current Circumstance and Operating State

• Risk Management

• Strong Portfolio against COVID-19 Impact

• Maintained Financial Solidity for Sustainable Growth

• Our Progress to Strengthen Operations

• Mid- to Long-term Thought-provoking on COVID-19

• Transformation Toward a New Normal

• The Terumo Purpose Is Even Clearer

@